These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21537424)

  • 21. Vildagliptin.
    Henness S; Keam SJ
    Drugs; 2006; 66(15):1989-2001; discussion 2002-4. PubMed ID: 17100408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Kim JH; Kim SS; Baek HS; Lee IK; Chung DJ; Sohn HS; Bae HY; Kim MK; Park JH; Choi YS; Kim YI; Hahm JR; Lee CW; Jo SR; Park MK; Lee KJ; Kim IJ
    Diabetes Metab J; 2016 Jun; 40(3):230-9. PubMed ID: 27098505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study.
    Chen Y; Li Q; Han Y; Ji H; Gu M; Bian R; Ding W; Cheng J; Mu Y
    Diabetes Ther; 2020 Jan; 11(1):247-257. PubMed ID: 31823167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.
    Blüher M; Kurz I; Dannenmaier S; Dworak M
    World J Diabetes; 2012 Sep; 3(9):161-9. PubMed ID: 23125906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
    El Ebrashy I; El Kafrawy N; Raouf R; Yousry D
    Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
    Ahrén B; Pacini G; Foley JE; Schweizer A
    Diabetes Care; 2005 Aug; 28(8):1936-40. PubMed ID: 16043735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.
    Göke R; Bader G; Dworak M
    Diabetes Ther; 2014 Jun; 5(1):183-91. PubMed ID: 24643724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Croxtall JD; Keam SJ
    Drugs; 2008; 68(16):2387-409. PubMed ID: 18973400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
    Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
    Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin-based therapies in type 2 diabetes mellitus.
    Chia CW; Egan JM
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan.
    Odawara M; Sagara R
    J Diabetes Metab Disord; 2015; 15():21. PubMed ID: 27382546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
    Halimi S; Schweizer A; Minic B; Foley J; Dejager S
    Vasc Health Risk Manag; 2008; 4(3):481-92. PubMed ID: 18827867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.